NASDAQ:DEPO - Depomed Stock Price, Price Target & More

$6.79 +0.11 (+1.65 %)

(As of 04/23/2018 04:00 PM ET)

Previous Close$6.68

Today's Range$6.71 - $6.99

52-Week Range$4.31 - $12.49

Volume1.32 million shs

Average Volume1.16 million shs

Market Capitalization$424.29 million

P/E Ratio-5.43

Dividend YieldN/A

Beta1.19

About Depomed (NASDAQ:DEPO)

Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. Depomed, Inc. was founded in 1995 and is headquartered in Newark, California.

Receive DEPO News and Ratings via Email

Sign-up to receive the latest news and ratings for DEPO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNASDAQ:DEPO

CUSIP24990810

Webwww.depomedinc.com

Phone510-744-8000

Debt

Debt-to-Equity Ratio3.21%

Current Ratio0.74%

Quick Ratio0.70%

Price-To-Earnings

Trailing P/E Ratio-5.43

Forward P/E Ratio-6.59

P/E GrowthN/A

Sales & Book Value

Annual Sales$380.72 million

Price / Sales1.13

Cash Flow$0.8498 per share

Price / Cash7.99

Book Value$2.69 per share

Price / Book2.52

Profitability

EPS (Most Recent Fiscal Year)($1.26)

Net Income$-102,490,000.00

Net Margins-26.92%

Return on Equity-45.19%

Return on Assets-8.39%

Miscellaneous

Employees434

Outstanding Shares63,520,000

How to Become a New Pot Stock Millionaire

Depomed (NASDAQ:DEPO) Frequently Asked Questions

What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

How were Depomed's earnings last quarter?

Depomed (NASDAQ:DEPO) released its earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.15 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.10 by $0.05. The specialty pharmaceutical company had revenue of $94.41 million for the quarter, compared to the consensus estimate of $88.75 million. Depomed had a negative net margin of 26.92% and a negative return on equity of 45.19%. View Depomed's Earnings History.

When is Depomed's next earnings date?

Depomed is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Depomed.

What price target have analysts set for DEPO?

8 brokers have issued 12 month target prices for Depomed's shares. Their forecasts range from $5.00 to $14.00. On average, they anticipate Depomed's share price to reach $8.75 in the next twelve months. View Analyst Ratings for Depomed.

Who are some of Depomed's key competitors?

Some companies that are related to Depomed include Mirati Therapeutics (MRTX), Eagle Pharmaceuticals (EGRX), Collegium Pharmaceutical (COLL), Deciphera Pharmaceuticals (DCPH), CymaBay Therapeutics (CBAY), Urogen Pharma (URGN), OptiNose (OPTN), Adamas Pharmaceuticals (ADMS), NuCana (NCNA), GlycoMimetics (GLYC), Vanda Pharmaceuticals (VNDA), Karyopharm Therapeutics (KPTI), Dova Pharmaceuticals (DOVA), ANI Pharmaceuticals (ANIP), BeyondSpring (BYSI), Rocket Pharmaceuticals (RCKT), Omeros (OMER) and AMAG Pharmaceuticals (AMAG).

Who are Depomed's key executives?

Depomed's management team includes the folowing people:

Mr. August J. Moretti, CFO & Sr. VP (Age 67)
Mr. Matthew M. Gosling, Sr. VP, Gen. Counsel & Sec. (Age 47)
Mr. Arthur Joseph Higgins, Chief Exec. Officer, Pres and Director (Age 62)
Mr. Sean P. McKercher, Sr. VP of Operations & Bus. Relationships
Dr. Santosh J. Vetticaden M.D., Ph.D., Sr. VP and Chief Medical & Scientific Officer (Age 59)

Has Depomed been receiving favorable news coverage?

Headlines about DEPO stock have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Depomed earned a media sentiment score of 0.17 on Accern's scale. They also assigned news headlines about the specialty pharmaceutical company an impact score of 47.92 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Depomed's major shareholders?

Depomed's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include STARBOARD VALUE LP (7.70%). Company insiders that own Depomed stock include Arthur J Higgins, August J Moretti, Matthew M Gosling and Thadd M Vargas. View Institutional Ownership Trends for Depomed.

How do I buy shares of Depomed?

Shares of DEPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Depomed's stock price today?

One share of DEPO stock can currently be purchased for approximately $6.79.

How big of a company is Depomed?

Depomed has a market capitalization of $424.29 million and generates $380.72 million in revenue each year. The specialty pharmaceutical company earns $-102,490,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Depomed employs 434 workers across the globe.

How can I contact Depomed?

Depomed's mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company can be reached via phone at 510-744-8000 or via email at [email protected]

MarketBeat Community Rating for Depomed (DEPO)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		411 (Vote Outperform)
Underperform Votes:		301 (Vote Underperform)
Total Votes:		712

MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe DEPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DEPO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Depomed (NASDAQ:DEPO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

8 Wall Street analysts have issued ratings and price targets for Depomed in the last 12 months. Their average twelve-month price target is $8.75, suggesting that the stock has a possible upside of 28.87%. The high price target for DEPO is $14.00 and the low price target for DEPO is $5.00. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.25	2.33	2.33	2.22
Ratings Breakdown:	0 Sell Rating(s) 6 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 5 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$8.75	$9.5556	$11.2222	$12.6667
Price Target Upside:	28.87% upside	46.78% upside	34.72% upside	135.00% upside

Depomed (NASDAQ:DEPO) Consensus Price Target History

Price Target History for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ:DEPO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/23/2018	Mizuho	Reiterated Rating	Buy	$9.00	High
3/2/2018	Roth Capital	Set Price Target	Buy	$10.00	Medium
3/1/2018	Piper Jaffray	Reiterated Rating	Hold	$8.00	Medium
12/7/2017	Royal Bank of Canada	Set Price Target	Hold	$9.00	Medium
11/10/2017	UBS	Boost Price Target	Neutral	$6.00 -> $7.00	N/A
11/9/2017	Morgan Stanley	Upgrade	Underweight -> Equal Weight		N/A
8/8/2017	Janney Montgomery Scott	Downgrade	Buy -> Neutral	$18.00 -> $8.00	High
5/15/2017	Cantor Fitzgerald	Set Price Target	Hold	$14.00	Medium
3/30/2017	JMP Securities	Reiterated Rating	Outperform	$30.00 -> $16.00	High
11/8/2016	Leerink Swann	Set Price Target	Buy	$22.00	N/A

(Data available from 4/23/2016 forward)

Depomed (NASDAQ:DEPO) Earnings History and Estimates Chart

Earnings by Quarter for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ:DEPO) Earnings Estimates

2018 EPS Consensus Estimate: $0.38

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$0.03	$0.03	$0.03
Q2 2018	1	$0.09	$0.09	$0.09
Q3 2018	1	$0.12	$0.12	$0.12
Q4 2018	1	$0.14	$0.14	$0.14

Depomed (NASDAQ DEPO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018		$0.12					N/A
2/27/2018	Q4 2017	$0.10	$0.15	$88.75 million	$94.41 million	View	Listen
11/7/2017	Q3 2017	$0.12	$0.14	$99.11 million	$95.40 million	View	N/A
8/7/2017	Q2 2017	$0.09	($0.43)	$100.40 million	$100.00 million	View	Listen
5/9/2017	Q1 2017	($0.25)	($0.43)	$99.48 million	$95.00 million	View	Listen
2/21/2017	Q4 2016	$0.3550	$0.48	$123.00 million	$123.90 million	View	Listen
11/7/2016	Q3	$0.35	$0.28	$127.22 million	$111.00 million	View	Listen
8/3/2016	Q2	$0.26	$0.27	$118.20 million	$116.70 million	View	Listen
5/5/2016	Q1	$0.17	$0.12	$106.88 million	$104.60 million	View	Listen
2/22/2016	Q415	$0.29	$0.16	$110.19 million	$111.20 million	View	Listen
11/9/2015	Q3	$0.19	$0.33	$101.64 million	$105.00 million	View	Listen
7/29/2015	Q215	($0.45)	$0.27	$88.33 million	$94.30 million	View	Listen
5/11/2015	Q115	$0.07	($0.13)	$33.80 million	$31.70 million	View	Listen
2/23/2015	Q414	$0.07	$0.21	$44.66 million	$33.90 million	View	Listen
11/5/2014	Q314	($0.04)	($0.01)	$41.50 million	$51.49 million	View	Listen
8/6/2014	Q214	($0.06)	($0.03)	$38.03 million	$67.70 million	View	Listen
5/8/2014	Q114	$0.11	($0.04)	$53.57 million	$76.50 million	View	Listen
3/12/2014	Q413	($0.21)	$0.72	$19.06 million	$40.60 million	View	Listen
11/5/2013	Q313	$0.07	$0.11	$35.55 million	$37.50 million	View	Listen
8/7/2013	Q2 2013	($0.05)	$0.01	$29.87 million	$30.00 million	View	Listen
5/8/2013	Q1 2013	($0.06)	($0.10)	$28.93 million	$26.20 million	View	Listen
2/20/2013	Q4 2012	($0.11)	($0.07)	$26.48 million	$26.60 million	View	Listen
11/5/2012	Q312	($0.11)	($0.03)	$28.06 million	$33.30 million	View	N/A
8/2/2012		($0.22)	($0.28)			View	N/A
5/8/2012		($0.24)	($0.16)			View	N/A
3/8/2012		($0.31)	($0.25)			View	N/A
11/1/2011		($0.23)	($0.15)			View	N/A
8/1/2011		($0.05)	($0.11)			View	N/A
5/5/2011		$1.05	$1.77			View	N/A
3/3/2011		$0.06	$0.03			View	N/A
11/1/2010	Q3 2010	($0.02)	$0.04			View	N/A
8/5/2010	Q2 2010	$0.04	$0.08			View	N/A
4/29/2010	Q1 2010	($0.07)	($0.07)			View	N/A
3/4/2010	Q4 2009	($0.13)	($0.07)			View	N/A
10/29/2009	Q3 2009	($0.06)	($0.10)			View	N/A
7/30/2009	Q2 2009	($0.19)	($0.19)			View	N/A
5/4/2009	Q1 2009	($0.22)	($0.20)			View	N/A
3/5/2009	Q4 2008	($0.26)	($0.22)			View	N/A
10/30/2008	Q3 2008	($0.15)	($0.12)			View	N/A
7/31/2008	Q2 2008	($0.22)	($0.03)			View	N/A
5/1/2008	Q1 2008		($0.16)			View	N/A
3/6/2008	Q4 2007	$0.40	$0.44			View	N/A

(Earnings results data provided by Zacks Investment Research)

Depomed (NASDAQ:DEPO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Depomed (NASDAQ DEPO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.27%
Institutional Ownership Percentage: 91.63%

Insider Trading History for Depomed (NASDAQ:DEPO)

Institutional Ownership by Quarter for Depomed (NASDAQ:DEPO)

Depomed (NASDAQ DEPO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2018	Matthew M. Gosling	SVP	Sell	45,519	$6.58	$299,515.02
12/14/2017	Arthur J. Higgins	Insider	Buy	75,000	$8.16	$612,000.00
6/12/2017	Arthur J Higgins	Insider	Buy	15,000	$9.92	$148,800.00
11/14/2016	August J Moretti	CFO	Sell	5,000	$20.84	$104,200.00	26,680
9/21/2016	Thadd M Vargas	VP	Sell	11,250	$25.00	$281,250.00	73,086
8/10/2016	August J. Moretti	CFO	Sell	5,000	$21.40	$107,000.00
8/10/2016	Thadd M Vargas	VP	Sell	26,290	$20.92	$549,986.80	84,336
5/23/2016	Thadd M Vargas	VP	Sell	15,000	$20.00	$300,000.00	109,297
5/10/2016	Thadd M Vargas	VP	Sell	15,000	$17.64	$264,600.00	124,297
5/9/2016	August J Moretti	CFO	Sell	5,000	$18.00	$90,000.00	22,879
3/11/2016	Thadd M Vargas	VP	Sell	23,000	$16.00	$368,000.00	137,737
12/3/2015	August J. Moretti	CFO	Sell	15,000	$18.11	$271,650.00	21,319
6/12/2015	Thadd M Vargas	VP	Sell	5,000	$20.70	$103,500.00
12/2/2014	August J Moretti	CFO	Sell	5,339	$15.85	$84,623.15
12/2/2014	James A Schoeneck	CEO	Sell	36,727	$15.85	$582,122.95
12/2/2014	Thadd M Vargas	VP	Sell	8,247	$15.85	$130,714.95
11/19/2014	Matthew M Gosling	VP	Sell	71,000	$15.36	$1,090,560.00
3/14/2014	James Schoeneck	CEO	Sell	17,000	$14.54	$247,180.00
3/14/2014	Matthew Gosling	VP	Sell	21,875	$14.74	$322,437.50	11,396
12/2/2013	Michael Md Sweeney	CMO	Sell	4,270	$8.40	$35,868.00	9,084
12/2/2013	Thadd Vargas	VP	Sell	5,296	$8.40	$44,486.40	61,698
5/10/2013	James A Schoeneck	CEO	Buy	25,000	$5.11	$127,750.00
3/6/2013	Karen A Dawes	Director	Buy	2,000	$5.96	$11,920.00
8/14/2012	Peter D Staple	Director	Buy	5,000	$5.01	$25,050.00

(Data available from 1/1/2013 forward)

Depomed (NASDAQ DEPO) News Headlines

Source:

Date	Headline
	Depomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate Communications finance.yahoo.com - April 20 at 5:00 PM
	Depomed (DEPO) Downgraded to "Sell" at BidaskClub www.americanbankingnews.com - April 19 at 1:56 PM
	Depomed Announces the Appointment of John B. Thomas as Senior Vice President, Investor Relations and Corporate ... www.globenewswire.com - April 17 at 5:27 PM
	Recent Analysis Shows Urban Outfitters, Depomed, Helios and Matheson Analytics, Keryx Biopharmaceuticals ... globenewswire.com - April 16 at 8:45 AM
	Depomed (DEPO) Rating Lowered to Neutral at Janney Montgomery Scott www.americanbankingnews.com - April 12 at 9:00 PM
	Does Depomed Inc’s (NASDAQ:DEPO) Past Performance Indicate A Weaker Future? finance.yahoo.com - April 12 at 5:05 PM
	Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) globenewswire.com - April 9 at 8:59 AM
	Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) finance.yahoo.com - April 9 at 8:59 AM
	Piper Jaffray Analysts Give Depomed (DEPO) a $9.00 Price Target www.americanbankingnews.com - April 7 at 12:26 PM
	Form 3 DEPOMED INC For: Apr 02 Filed by: Bukofzer Stan www.streetinsider.com - April 5 at 10:52 AM
	Depomed Sees Unusually High Options Volume (DEPO) www.americanbankingnews.com - April 5 at 6:30 AM
	When Will Depomed Inc (NASDAQ:DEPO) Become Profitable? finance.yahoo.com - April 3 at 5:04 PM
	Depomed (DEPO) Names Stan Bukofzer, MD as Senior Vice President and Chief Medical and Scientific Officer www.streetinsider.com - April 2 at 5:02 PM
	Depomed Announces the Appointment of Stan Bukofzer, MD as Senior Vice President and Chief Medical and Scientific ... www.globenewswire.com - April 2 at 5:02 PM
	Depomed Announces the Appointment of Stan Bukofzer, M.D. as Senior Vice President and Chief Medical and Scientific Officer finance.yahoo.com - April 2 at 5:02 PM
	Depomed (DEPO) PT Lowered to $6.00 www.americanbankingnews.com - April 1 at 11:24 AM
	Depomed (DEPO) Receives Consensus Recommendation of "Hold" from Brokerages www.americanbankingnews.com - March 31 at 7:46 PM
	Depomed Distances Itself From Nucynta seekingalpha.com - March 27 at 9:07 AM
	Depomed (DEPO) Lowered to Sell at BidaskClub www.americanbankingnews.com - March 26 at 11:30 PM
	Depomed (DEPO) Downgraded by ValuEngine to Strong Sell www.americanbankingnews.com - March 25 at 6:58 PM
	BidaskClub Downgrades Depomed (DEPO) to Strong Sell www.americanbankingnews.com - March 25 at 9:30 AM
	Mizuho Reaffirms Buy Rating for Depomed (DEPO) www.americanbankingnews.com - March 23 at 1:30 PM
	Depomed Announces New Corporate Headquarters - GlobeNewswire (press release) globenewswire.com - March 21 at 9:42 AM
	Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis finance.yahoo.com - March 20 at 4:52 PM
	Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis finance.yahoo.com - March 19 at 4:51 PM
	Depomed Announces New Corporate Headquarters finance.yahoo.com - March 19 at 8:56 AM
	Should You Follow This Trend For Depomed Inc (NASDAQ:DEPO)? finance.yahoo.com - March 16 at 8:56 AM
	Global Pain Management Therapeutics Market Opportunities 2018: Mallinckrodt Pharmaceuticals, Pfizer, Purdue Pharma L.P, Novartis AG www.marketwatch.com - March 14 at 9:24 AM
	Form 4 DEPOMED INC For: Mar 07 Filed by: Gosling Matthew M www.streetinsider.com - March 10 at 8:50 AM
	Matthew M. Gosling Sells 45,519 Shares of Depomed Inc (DEPO) Stock www.americanbankingnews.com - March 9 at 9:28 PM
	PDL BioPharma (PDLI) Q4 Earnings Beat, Revenues Rise Y/Y www.msn.com - March 9 at 6:12 PM
	Report: Exploring Fundamental Drivers Behind Cenovus Energy, Depomed, Zoe's Kitchen, NetApp, Keryx Biopharmaceuticals, and Ocular Therapeutix — New Horizons, Emerging Trends, and Upcoming Developments finance.yahoo.com - March 9 at 9:05 AM
	Exploring Depomed’s Financial Performance Today finance.yahoo.com - March 8 at 8:58 AM
	Inside Depomed’s Portfolio: The Key Drugs finance.yahoo.com - March 7 at 5:56 PM
	Depomed Inc (DEPO) Receives Consensus Rating of "Hold" from Analysts www.americanbankingnews.com - March 6 at 7:36 PM
	Depomed to Present at Healthcare Conferences in March finance.yahoo.com - March 6 at 5:18 PM
	What this East Bay company is saving — and losing — by moving to the Midwest - San Francisco Business Times www.bizjournals.com - March 4 at 8:48 AM
	Depomed (DEPO) Given a $10.00 Price Target at Roth Capital www.americanbankingnews.com - March 3 at 5:38 PM
	Bogle Investment Management L P DE Has $8.13 Million Holdings in Depomed Inc (DEPO) www.americanbankingnews.com - March 3 at 4:52 AM
	Depomed (DEPO) Receives Hold Rating from Piper Jaffray Companies www.americanbankingnews.com - March 1 at 8:13 PM
	Depomed Sees Unusually Large Options Volume (DEPO) www.americanbankingnews.com - March 1 at 7:24 AM
	Here's Why Depomed Inc Fell as Much as 13.8% Today finance.yahoo.com - February 28 at 5:35 PM
	Depomed (DEPO) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS www.americanbankingnews.com - February 28 at 11:16 AM
	BRIEF-Depomed Reports Q4 GAAP Loss Per Share $0.52 www.reuters.com - February 27 at 5:31 PM
	Depomed, Inc. to Host Earnings Call finance.yahoo.com - February 27 at 5:31 PM
	Depomed reports 4Q loss finance.yahoo.com - February 27 at 5:31 PM
	State of Wisconsin Investment Board Boosts Holdings in Depomed Inc (DEPO) www.americanbankingnews.com - February 27 at 3:45 PM
	Systematic Financial Management LP Has $1.83 Million Stake in Depomed Inc (DEPO) www.americanbankingnews.com - February 25 at 11:30 AM
	Depomed (DEPO) Scheduled to Post Earnings on Tuesday www.americanbankingnews.com - February 22 at 8:16 PM
	Depomed (DEPO) Upgraded by BidaskClub to Hold www.americanbankingnews.com - February 21 at 6:26 AM

Depomed (NASDAQ:DEPO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Depomed (NASDAQ:DEPO) Income Statement, Balance Sheet and Cash Flow Statement

Depomed (NASDAQ DEPO) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff